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TumorSignaling initiated by secreted glycoproteins of the Wnt family regulates many aspects of embryonic develop-
ment and it is involved in homeostasis of adult tissues. In the gastrointestinal (GI) tract the Wnt pathway main-
tains the self-renewal capacity of epithelial stem cells. The stem cell attributes are conferred by mutual
interactions of the stem cell with its local microenvironment, the stem cell niche. The niche ensures that the
threshold of Wnt signaling in the stem cell is kept in physiological range. In addition, the Wnt pathway involves
various feedback loops that balance the opposing processes of cell proliferation and differentiation. Today, we
have compelling evidence that mutations causing aberrant activation of the Wnt pathway promote expansion
of undifferentiated progenitors and lead to cancer.
The review summarizes recent advances in characterization of adult epithelial stem cells in the gut. We mainly
focus on discoveries related to molecular mechanisms regulating the output of the Wnt pathway. Moreover,
we present novel experimental approaches utilized to investigate the epithelial cell signaling circuitry in vivo
and in vitro. Pivotal aspects of tissue homeostasis are often deduced from studies of tumor cells; therefore, we
also discuss some latest results gleaned from the deep genome sequencing studies of human carcinomas of the
colon and rectum.
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ExtracellularWnt proteins act inmetazoans asmorphogens to regu-
late diverse processes throughout embryonic development, such as cell
proliferation, differentiation, cell migration and cell polarity. In adult-
hood, Wnt signaling is essential for the maintenance of somatic stem
cell and committed progenitor cell compartments. The pathway is also
involved in tissue regenerative processes following injury [1,2]. Overall,
there are at least three distinct “branches” of Wnt signaling (reviewed
in [3]). The best studied so called “canonical” pathway depends on β-
catenin as its key effector (Fig. 1). Besides its engagement in cadherin-
based adherens junctions [4], β-catenin associates with DNA-binding
Fig. 1. Canonical Wnt signaling. In the absence of theWnt signal, cytosolic β-catenin is bound by amultimeric destruction complex that includes Axin and APC. Beta-catenin is then phos-
phorylated by serine/threonine kinases CK1α and GSK3α/β. The N-terminal phosphorylated amino acid residues are recognized by β-TrCP, a component of SKP1-cullin-F-box (SCF) ubiq-
uitin ligase, and the ubiquitinylated protein is destroyed by the proteasome. The presence of Wnt ligand bridges the Frizzled-LRP proteins, leading to recruitment of the destruction
complex to cytosolic tails of clustered LRP receptors (simpliﬁed for clarity). The complex can still bind β-catenin, but its ubiquitinylation is inhibited. Consequently, newly synthesized
β-catenin molecules accumulate in the cytoplasm and shuttle to the cell nucleus to transactivate expression of TCF-dependent target genes. In an alternative model, activeWnt signaling
disrupts theβ-catenin destruction complex and inhibitsβ-catenin phoshorylation (not depicted, see the text for additional details). The secretedWnt pathway agonists, the RSPOproteins,
augment theWnt circuit by promoting stabilization of Frizzled and LRP proteins. RSPOs forma ternary complexwith their LGR4/5 receptor and transmembrane E3ubiquitin ligase proteins
ZNRF3 and RNF43, thereby inhibiting turnover of the Wnt receptors.
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TCF) family (further referred to as TCFs) to modulate expression of
context-speciﬁc target genes. In the absence of the Wnt stimulus, cyto-
solic β-catenin is marked for degradation by a protein complex that in-
cludes serine/threonine kinases casein kinase 1 alpha (CK1α) and
glycogen synthase kinase 3 (GSK3) [5]. Scaffolding of the kinases and
β-catenin is mediated by axis inhibition protein (Axin) [6] and adeno-
matous polyposis coli (APC) tumor suppressors [7]. Ultimately, N-
terminally phosphorylated β-catenin is ubiquitinated by F-box-
containing beta-transducin repeat containing (β-TrCP) E3 ubiquitin
protein ligase and subsequently destroyed by the proteasome [8,9]. In
unstimulated cells the TCF proteins are associated with transcriptional
repressors of the groucho/transducin-like enhancer of split (TLE) family
and block expression of Wnt-responsive genes [10]. Wnt molecules
bind to a receptor complex composed of a seven-transmembrane recep-
tor of the Frizzled family and co-receptor low density lipoprotein
receptor-related protein (LRP) [11]. The ligand–receptor engagement
triggers a cascade of events that include phoshorylation of the adaptor
protein Disheveled (Dvl) by CK1ε [12]. In addition, the intracellular por-
tion of LRP is phosphorylated by CK1γ and GSK3, and the LRP–Axin
complex is subsequently formed [13]. Simultaneously, the phosphory-
lated amino acid residues in Axin (these modiﬁcations are catalyzed
by GSK3) are removed by protein phosphatase 1 (PP1) [14] or PP2A
[15]. The dephosphorylated protein constitutes “closed” conformation
that is unable to interact with β-catenin and, consequently, β-catenin
phosphorylation is inhibited. In an alternative model proposed by Li
and colleagues, the β-catenin destruction complex remains intact in
the Wnt signal receiving cell; however, active signaling suppresses β-
catenin ubiquitination, which leads to the saturation of the complex
with phosphorylated β-catenin [16]. In any case, β-catenin accumulates
in the cell cytoplasm and nucleus, where it displaces the groucho/TLEproteins from TCFs. Beta-catenin contains a transactivation domain,
and TCF-β-catenin complexes thus act as bipartite transcriptional acti-
vators of speciﬁc target genes such as c-myc [17], cyclin D1 [18,19],
CD44 [20] and Axin2 [21]—for a comprehensive list of Wnt target
genes, please refer to the Wnt homepage www.stanford.edu/group/
nusselab/cgi-bin/wnt/target_genes.
The β-catenin-independent, ‘noncanonical’ Wnt signaling cascades
utilize distinct signaling mechanisms to relay the signal from the Wnt
receptor complex. The planar cell polarity (PCP) pathway activates
small GTPases ras-related C3 botulinum toxin substrate 1 (Rac1) and
ras homolog gene family member A (RhoA). The pathway also includes
protein kinases rho-associated, coiled-coil-containing protein kinase
(ROCK) and c-Jun N-terminal kinase (JNK) that in turn induce cytoskel-
etal remodeling or elicit a transcriptional response, respectively [22].
PCP signaling is implicated in the establishment of cell polarity and
cell migration [23,24]. The second relatively well-characterized non-
canonical pathway, Wnt/Ca2+ signaling, stimulates phospholipase C
(PLC) through the action of heterotrimeric G proteins. The resultingmo-
bilization of intracellular Ca2+ activates Ca2+-dependent effectors that
include calcium calmodulinmediated kinase II (CAMKII), protein kinase
C (PKC) and calcineurin (reviewed in [25]). The Wnt/Ca2+ signaling
branch is implicated in inﬂammation and promotion of cancer [26].
Wnt ligands can also engage tyrosine kinase-like orphan receptor 2
(ROR2) [27,28] and receptor-like tyrosine kinase (RYK) [29] as recep-
tors; however, there is only little insight into these alternative Wnt sig-
naling pathways. Importantly, despite the general consensus on the key
role of β-catenin-independent Wnt signaling in development and can-
cer, the precise molecular mechanisms of the noncanonical pathways
remain mostly unknown. This is mainly due to the fact that in contrast
to Wnt/β-catenin signaling, the ﬁeld of the noncanonical pathways suf-
fers from the lack of suitable reagents and robust functional assays.
Fig. 2. Cellular architecture in the crypt of the small intestine. The intestinal homeostasis is
sustained by crypt base columnar (CBC) stem cells (depicted in green) that occupy the
crypt ﬂoor in positions alternating with post-mitotic Paneth cells (dark blue). The stem
cells stochastically self-renew or give rise to committed daughter transit amplifying
(TA) cells (yellow). As the progenitors further ascend the crypt, mesenchyme (orange)-
derived BMP signaling promotes their differentiation towards predominant absorptive
enterocytes (pink), or secretory goblet (purple) and enteroendocrine cells (light blue)
that produce mucus and release peptide hormones, respectively. The pluripotency and
proliferation of stem cells is maintained by Wnt cues, redundantly supplied by the stem-
neighboring Paneth cells and subepithelial myoﬁbroblasts (brown). A separate pool of
more quiescent stem cells has been proposed to reside at the position “+4” from the
crypt base. These dormant cells mobilize when CBC cells have been depleted upon tissue
damage. Recent evidence, however, suggests that Dll-positive progenitor cells from the
+5 position revert to stem-like cells to replenish the crypt on mucosal injury. Numbers
assigned to individual cell positions in the crypt are also indicated.
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ceptors. It is presumed that the combinatorial complexity among indi-
vidual ligands and their cognate receptors (and co-receptors) dictates
the particular type of the downstream pathway. SomeWnts (including
Wnt1 andWnt3a) preferentially trigger canonical signaling, other such
as Wnt5a and Wnt11 initiate the β-catenin-independent pathways
(reviewed in [30]. Notably, the PCP andWnt/ROR pathways can antag-
onize the canonical Wnt cascade; this indicates possible crosstalk
among various types ofWnt signaling [31,32]. The output ofWnt signal-
ing is regulated at virtually all cellular levels. Since detailed description
of theWnt signal relay andmodulation goes beyond the scope of this re-
view, we refer to some excellent recent review articles for additional in-
formation [25,33–37]. Here, we will brieﬂy summarize some
extracellular and membrane activators or inhibitors of Wnt signaling,
as these molecules regulate the interaction between the signal-
receiving cell and its tissue microenvironment. Secreted polypeptides
of the Dickkopf (Dkk) family [38–40], sclerostin (Sost) [41,42] and
Wnt modulator in surface ectoderm [(WISE); also known as sclerostin
domain containing 1 (Sostdc1)] [43] interfere with canonical signaling
by binding to the LRP co-receptor. In contrast, two distinct classes of se-
creted Wnt pathway agonists, Norrin [44] and R-spondins (Rspos)
[45,46], augment the Wnt activity. Independently of Wnts, Norrin po-
tentiates β-catenin signaling by direct binding to Frizzled, thereby pro-
moting its oligomerization [47]. Rspos form a complex with their
receptor leucine-rich G protein coupled receptor 4/5/6 (LGR4/5/6)
[48–50]. Rspo also associates with zinc and ring ﬁnger 3 (Znfr3) and
ring ﬁnger 43 (Rnf43) transmembrane ubiquitin ligases that were iden-
tiﬁed as negative regulators of Wnt signaling. These related ligases de-
crease the stability of Frizzled through ubiquitin-mediated
degradation. Rspo binding promotes removal of Znfr3 from the plasma
membrane, and consequently the levels of Frizzled (and also LRP) are
increased, which leads to the enhanced Wnt response [51,52]. In an
analogous way, the LRP6 co-receptor is endocytosed upon its binding
to Dkk1 and transmembrane protein Kremen; this, however, leads to
downregulation of Wnt signaling [53].
2. Cell renewal in the GI tract
The architecture of the small intestine and colon is designed tomax-
imize the surface of the organ to resorb nutrients and water from food.
In both anatomical segments of the GI tract, the single-cell epithelial
sheet penetrates into the underlying connective tissue of lamina propria
to form tubular glands called crypts. In addition, luminal protrusions of
the mucosa termed villi are present in the small intestine to further en-
hance the surface area.
The epithelial lining represents one of the most intensively self-
replenishing organs in mammals. With a rate of entire renewal every
3–5 days along the crypt-villus axis [54], this dynamic and organized
cell turnover represents an attractive paradigm for tissue maintenance
studies (reviewed in [55]). The homeostasis is sustained by crypt-
resident multipotent intestinal stem cells (ISCs). They give rise to a
pool of highly proliferative progenitors called transit-amplifying (TA)
cells. These cells undergo several rounds of cell divisions and commence
differentiation towards all intestinal lineages as they migrate upwards
the crypt length to the crypt oriﬁce (Fig. 2). The villi receive fullymature
cells that fulﬁll the digestion- and resorption-associated functions of the
tissue. While absorptive enterocytes participate in transport processes,
goblet cells secrete mucus to lubricate the mucosal surface. Moreover,
rare peptide hormone-releasing enteroendocrine cells are found
scattered among the cells of major epithelial cell lineages. The ISCs of
the crypt also generate additional minor mucosal populations, such as
M cells that transport antigens from the intestinal lumen to underlying
Peyer's patches [56] and tuft cells, rare cells producing opioids and
enzymes involved in prostaglandin synthesis [57]. The continuous pro-
liferation of crypt cells is counterbalanced by cell shedding at the tip of
the villus. Paneth cells of the small intestine represent an exception tothis scheme. These bacteriostatic compound-producing cells do not fol-
low the migration pattern but descend towards the crypt base, where
they persist for 6–8 weeks [58]. Analogous to the Paneth cells, a subset
of enteroendocrine cells have been observed to drift towards the bot-
tom part of the crypt. Remarkably, these cells are hallmarked by co-
expression of both stem cell and mature endocrine markers [59]. The
situation in the colon reminds the small intestine; however, its surface
does not contain the protruding villi, and the Paneth cells are not
present in the colonic crypts.2.1. ISCs
To date, two populations of putative ISCs have been identiﬁed in the
small intestine epithelium; the populations occupy distinct but neigh-
boring locations in the crypt. Crypt base columnar (CBC) ISCs are slen-
der, actively dividing cells that are interspersed among the Paneth
cells at the most bottom part of the crypt (Fig. 2). CBC cells can be visu-
alized using their uniquemarker Lgr5. Barker and colleagues produced a
knock-in allele into the Lgr5 locus by inserting the EGFP-IRES-CreERT2
expression cassette downstream of the translation-initiation codon of
the gene [60]. The mouse (designated Lgr5-EGFP-IRES-CreERT2)
allowed direct visualization of Lgr5-positive cells in tissues by means
of EGFP detection. Moreover, upon crossing to Rosa26-lacZ reporter
(Rosa26R) mice and activation of Cre enzyme by tamoxifen the allele
enabled long-term lineage tracing of the progeny of CBC cells. The
“stemness” of CBC cells, i.e. longevity and potency to produce all intesti-
nal cell lineages,was also conﬁrmedby regeneration of the damaged co-
lonic epithelium from single Lgr5+ cells [61]. Moreover, expression
proﬁling of Lgr5-EGFP-IRES-CreERT2 cells (fractionated according to
the EGFP production) unraveled the gene signature of Lgr5+ CBC cells
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achaete-scute complex homolog 2 (Ascl2), since its conditional ablation
results in loss of CBCs. Conversely, the intestine-speciﬁc over-
expression of Ascl2 in transgenic mice was accompanied by marked en-
largement of the stem cell compartment [63]. In addition, CBC cell-
speciﬁcmarkers include Troy (alternative names—tumor necrosis factor
receptor superfamily,member 19 [TNFRSF19] or TAJ) [64], olfactomedin
4 (Olfm4) [65], and SPARC related modulator calcium binding 2
(Smoc2) [62]. Moreover, CBCs display highest expression of transmem-
brane ephrin type-B receptor 2 (EphB2), whereas EphB2 expression
progressively declines in TA cells as they migrate along the crypt-
villus axis, and Paneth cells are EphB2 negative. The gene expression
signature of crypt cells sorted from the mouse small intestine or
human colon according to EphB2 surface expression showed that the
EphB2high cell population indeed corresponds to CBCs [66].
A pool of slowly cycling stem cells has been proposed to co-inhabit
the intestinal crypt. Based on predominant location at the “+4” position
from the crypt base, several markers were identiﬁed in this stem cell
population. These include polycomb protein B lymphoma Mo-MLV in-
sertion region 1 homolog (Bmi1) [67], telomerase reverse transcriptase
(Tert) [68], homeobox-only protein (Hopx) [69], and leucine-rich re-
peats and immunoglobulin-like domains 1 (Lrig1) [70,71]. Several stud-
ies have described mobilization of otherwise quiescent Bmi1+ stem
cells upon radiation-induced injury [72] or diphtheria toxin-mediated
elimination of Lgr5+ cells engineered to produce the diphtheria toxin
receptor [73]. Recent effort signiﬁcantly contributed to elucidation of
the identity of “reserve” stem cells. Multicolor mRNA ﬂuorescence in
situ hybridization (FISH) assays and expression proﬁling revealed that
prospective markers of quiescent stem cells, Bmi1, Hopx and Tert are
broadly expressed throughout the crypt compartment and do not
mark a unique cell population within the crypt [62,74]. Moreover, no
other intestinal crypt cells but Paneth cells retained labels as revealed
by pulse-chase labeling using transgenic mice expressing histone 2B–
green ﬂuorescent protein (H2B-GFP) [75] or by multi-isotope imaging
mass spectrometry (MIMS) [76]. Of note, single-molecule FISH showed
that some proposed CBC cell markers such as CD133/prominin 1 [77,78]
andmusashi RNA-binding protein 1 (Msi1) [79] are not restricted to CBC
cells and these genes display expression along the crypt axis [74].
Interestingly, two progenitor populations have been demonstrated
to revert to stem-like cells to replenish the crypt upon extensive tissue
damage. These include short-lived progenitors of all secretory lineages
that express the Notch ligand delta-like 1 (Dll1) [80] or dedifferentiated
Paneth cells [75]. Very recently, Buczacki and colleagues re-examined
the nature of quiescent stem cells in the crypt [81]. The authors devised
a new strategy for labeling all crypt cells except the Paneth cells by tran-
sient expression of H2B-yellow ﬂuorescent protein (H2B-YFP). Several
days after the labeling all label-retaining cells (LRCs) were detected in
the lower part of the crypt. These LRCs co-expressed the CBC stem
cells marker Lgr5 as well as markers of the Paneth and enteroendocrine
cell lineages [e.g.matrixmetallopeptidase 7 (Mmp7) and chromogranin
A (Chga), respectively]. Moreover, after a longer period following initial
labeling, LRCs without any division converted to mature Paneth and
enteroendocrine cells. Intriguingly, isolated LRCs possess multi-lineage
growth potential and form so-called organoids in culture (see further).
To test whether LRCs display stem cell-like properties in vivo, Buczacki
and colleagues developed a novel dimerizable Cre recombinase meth-
odology to mark LRCs. In healthy mice, the marked cells did not divide;
however, upon tissue injury LRCs proliferated extensively and produced
clones comprising all epithelial cell types. These ﬁndings possibly
unify theories about the identity of intestinal stem cells. Actively cy-
cling Lgr5-positive CBC cells generate all epithelial cell lineages. The
cells also produce a population of non-dividing LRCs that differenti-
ate into Paneth and enteroendocrine cells. These precursor cells ex-
press markers for the proposed “+4” stem cells and can function as
quiescent stem cells activated when the tissue is damaged. In con-
clusion, crypt cells display substantial plasticity and the stemnessmight be extrinsically imposed on cells occupying the respective lo-
cation within the crypt.
2.2. Wnt signaling represents the principal force behind intestinal epitheli-
um homeostasis
Numerous studies conducted both in vivo and in vitro have ﬁrmly
established the role of Wnt signaling in the preservation of stem cell
proliferation and pluripotency (reviewed in [55]). Genetic disruption
of the pathway's ultimate effectors Tcf4 (ofﬁcial symbol Tcf7l2) [82,83]
or β-catenin (Ctnnb1) [84,85] are associated with demise of the intesti-
nal crypts. Similar collapse of the intestinal architecture occurs when
the Wnt cascade is counteracted through ectopic expression of the se-
creted Wnt antagonist Dkk1 [86,87]. Conversely, aberrant activation of
the Wnt pathway increases Lgr5+ stem cell numbers as observed
upon injection ofWnt agonist RSPO1 intomice [46]. The robust prolifer-
ation in the crypt is facilitated by direct repression of cell cycle inhibitor
p21Cip1/Waf1 by the Tcf4 target gene c-myc [88]. Expectedly, the crypt
progenitors are depleted by G1 arrest and concomitant differentiation
upon c-myc ablation [89]. Strikingly, in the colon the Tcf4 factor acts in
an opposing manner to restrict the expansion of the colonic epithelium
[90].
The identiﬁcation of ISCs was directly related to the analysis of TCF-
β-catenin-responsive genes in human tumor cells. The results of this
analysis were subsequently conﬁrmed in mouse intestinal tissue [88].
The expression of stem cell markers Ascl2, EphB2, Bmi1, Lgr5 and Tert
is governed by the canonical Wnt pathway [88,91–95]. Moreover, the
strength of the Wnt cascade is restrained in CBC cells by the pathway
negative feedback-loop mechanisms that involve upregulation of the
β-catenin negative regulator Axin2 [21] and expression of Frizzled-
speciﬁc ubiquitin ligases Rnf43 and Znfr3 [51,52]. The simultaneous
conditional ablation of both Rnf43 and Znrf3 in the mouse intestine in-
duces expansion of the proliferative zone of the crypts that eventually
leads to formation of intestinal adenomas [52]. In contrast, the genetic
inactivation of Lgr5 in the intestine results in no obvious phenotype.
However, deletion of the homologous Lgr4 gene has damaging effects
on crypt stem cells and Lgr4/5 double-deﬁciency leads to demise of in-
testinal crypts [49]. Since Lgr4 functions equivalently as the Rspo recep-
tor, the observed phenotypes might be explained by functional
redundancy of Lgr4 and Lgr5 [49,50,96]. Finally, another Wnt signaling
target gene Troy produces a transmembrane protein that suppresses
Wnt/Rspo signaling via its association with Lgr5 [64].
The noncanonical Wnt pathway activated byWnt5a is implicated in
regenerative processes of the GI tract. AlthoughWnt5a is crucial for em-
bryonic gut development, it is dispensable in homeostasis of postnatal
intestinal tissue [97]. However, in case of mucosal wounding Wnt5a
augments transforming growth factorβ (TGF-β) signaling to restrict ep-
ithelial proliferation and promote restoration of the proper tissue archi-
tecture [98]. Surprisingly, these outcomes are achieved through the
induction of cell cycle inhibitors such as p15INK4B [98] and do not com-
prehend inhibition of canonical Wnt signaling as previously assumed
[99,100].
2.3. The ISC niche
The stem cell permissive environment is constituted by neighboring
Paneth cells [101] and subepithelial myoﬁbroblasts that tightly line the
crypt base basal lamina [102]. This close association facilitates direct
supply of ICSs with essential pro-proliferative factors that include
Paneth-derived Dlls, epidermal growth factor (EGF), Wnt3 and
mesenchyme-secreted Wnt2b [101,103]. A subpopulation of c-Kit/
steel factor receptor (also designated CD117)-positive goblet cells of
the colonic crypt substitutes for the Paneth cells in the caudal regions
of the gut. These secretory cells provide Dll1/4 and EGF cues much like
their Paneth equivalents [104]; however, they are devoid of the Wnt
production [103]. Paneth cells and myoﬁbroblast-derived niches likely
Fig. 3. Intestinal organoid. Stereoscopic image of 4-day-old organoid established from a
single crypt of the mouse small intestine. Organoids growing in culture recapitulate the
cellular hierarchy of the epithelium. Stem cells are localized in crypt-like “budding” com-
partments; differentiated non-dividing cells move into villus-like regions, where are ﬁnal-
ly shed into the enclosed central lumen. Scale bar, 100 μm.
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the epithelium-restricted conditional inactivation of Wnt3 coincide
with depletion of ISCs [103].
TheWnt signaling cascade is tightly controlled to prevent (over)pro-
liferation of ISCs (reviewed in [105]). The expression of the Wnt cues
displays a diminishing slope along the crypt-villus axis [106]. In addi-
tion, theWnt proteins are locally attenuated at the+4 position by pro-
duction of the Wnt antagonists secreted Frizzled-related proteins
(sFRPs) [106]. Furthermore, the Wnt pathway output is modulated by
co-operative activity of the Hedgehog and bone morphogenic protein
(BMP) cascades [107]. In more detail, as the progenitor cells further de-
cline from the crypt base, the Hedgehog-induced, mesenchyme-to-
epithelium BMP signaling promotes differentiation while restraining
proliferation [108]. Importantly, in the colon ISCs are locally protected
from the pro-differentiation BMP signals by secreted stroma-derived
BMP antagonists gremlin 1/2 and chordin-like 1 [102]. In concordance
with this concept, inappropriate activation of Hedgehog signaling re-
sults in BMP-mediated depletion of the progenitor compartment
[107]. Conversely, shortage of the Hedgehog [109,110] and/or BMP sig-
nals [108,111] is associated with impaired Wnt control and results in
cancer development. Additionally, the mitogenic activity of Paneth
cell-derived EGF is counterbalanced by expression of pan-EGFR inhibi-
tor Lrig1 [70,71]. Accordingly, the genetic inactivation of Lrig1 results
in unrestricted precursor expansion predisposing to onset of intestinal
cancer [70,71].
The binary cell fate decisions between secretory versus absorptive
cell lineages are governed by the synergism between the Wnt and
Notch pathways (reviewed in [63]). Wnt signaling controls high
crypt-speciﬁc expression of EphB2 and EphB3 in CBCs or Paneth cells,
respectively, and establishes a gradient of repulsive EphB2/3-ephrin
B1 interaction that drives proper cell positioning along the crypt-villus
axis [112]. Moreover, the Wnt signals are required for commitment,
maturation and location of the Paneth cells [103,113–115]. Inactivation
of Wnt signaling target gene SRY-box containing gene 9 (Sox9) results in
the loss of Paneth cells [116,117]. The Notch1 and Notch2 receptors—
produced on CBC cells—engagewith their Dll1 and Dll4 ligands present-
ed by the Paneth cells [118,119]. The proliferation of the Notch signal-
receiving cell is then promoted by Notch-responsive gene hairy and
enhancer of split 1 (Hes1) that transcriptionally represses cyclin-
dependent kinase inhibitors p27Kip1 and p57Kip2 [120]. Consistently,
the Dll1/4 compound mutant mice display premature differentiation
of intestinal stem cells [119]. However, as mentioned previously, since
stem cells retain their clonogenic capacity in the absence of the Paneth
cells, the lateral Notch signals might be dispensable. Collectively, the
homeostasis of the intestinal epithelia is governed by an interconnected
circuitry of developmental signaling pathways that balance the oppos-
ing processes of cell proliferation and differentiation.
3. Experimental approaches to studying the gut epithelium in vitro
Until recently, the study of the bowel physiology has been restricted
to genetically manipulated model organisms or gut explants
transplanted into immunocompromised or syngeneic hosts [121]. In liv-
ing animals the organ is hardly accessible for direct experimental ma-
nipulation or consecutive examinations. Many attempts were made to
produce cultures mimicking growth and differentiation of the intestinal
tissue, but the experiments were for a long time unsuccessful. Themain
obstacle was the reduced viability of epithelial cells, which without the
support from the basement membrane and stroma underwent apopto-
sis [122,123]. Lately developed three-dimensional (3D) culture systems
preserved the tissues architecture and cellular differentiation; however,
these systems were restricted to embryonic gut tissue and explanted
cells displayed limited viability [124,125].
Recently, Ootani and colleagues established a long-term 3D culture
system to growexplants of themouse small or large intestine. The tissue
is propagated as expanding intestinal spheres in collagen using an air–liquid interface setting [126]. Moreover, Sato and co-workers developed
a straightforward methodology for continuous cultures of primary in-
testinal epithelium. This approach allows generation of sphere-like
“organoids” from resectedmouse crypts ormost interestingly, from sin-
gle Lgr5+ [127] or EphB2high [128] small intestinal or colonic cells, re-
spectively. These “mini-guts” fully resemble the intestinal architecture
with crypt- and villus-like cell compartments that enclose to forma cen-
tral lumen lined by differentiated cells (reviewed in [129]) (Fig. 3). Iso-
lated cells are grown inmatrigel, which simulates the native embedding
of the glands. The Wnt agonist Rspo, BMP-inhibitor Noggin and EGF
constitute the essential culture supplements to reproduce the stem
cell niche stimuli. In the crypt-like entities “budding” from the organoid
surface, theWnt cues are provided by the stem cell-neighboring Paneth
cells since conditional excision of Wnt3 halts organoid proliferation
[103]. Consistently, growth inWnt3−/− small intestinal organoids is re-
stored uponWnt3a administration or in co-culture with feeder cells de-
rived from the gut mesenchyme. In contrast, the colon-derived
organoids strictly rely on exogenous Wnt3a. The disparity in the Wnt
dependency of small intestinal versus colonic cultures underlines the al-
readymentioned fact that in the colonic crypts theWnt signal is mainly
provided by myoﬁbroblasts [103,104]. Interestingly, human biopsy-
derived colonic organoids require additional supplements for their sur-
vival. Addition of prostaglandin E2 blocks anoikis and potentiates
growth factor signaling [128]. Moreover, nicotinamide and small mole-
cule inhibitors of activin A receptor, type II-like kinase 4 (Alk4) and p38
kinase signiﬁcantly contribute to the long-term maintenance of prolif-
erating organoids [130].
The ex vivo intestinal culture systems represent an unprecedented
tool for therapeutic applications. Indeed, organoids can successfully en-
graft and regenerate chemically damagedmucosawhen introduced into
the recipient colon [61]. Interestingly, in the presence of exogenous
Wnt3a,mouse small intestine organoids change their crypt–villus archi-
tecture and form rounded cysts lacking differentiated cell types. Similar
“spheroids” can be derived from mouse or human tumors displaying
hyperactive Wnt signaling [101,127]. Very recently, Dekkers and col-
leagues generated intestinal organoids from the biopsies of patients suf-
fering from cystic ﬁbrosis, a disease caused by mutations in the cystic
ﬁbrosis transmembrane conductance regulator (CFTR) gene. Strikingly,
forskolin, the adenylate cyclase activator, induced rapid swelling
of organoids derived from control healthy individuals. However,
this effect—corresponding quantitatively to forskolin-induced anion
currents—was strongly reduced in CFTR-deﬁcient organoids. In addition,
the behavior was phenocopied when wild-type organoids were cul-
tured with CFTR-speciﬁc inhibitors. Even more interestingly, in the
mouse model of cystic ﬁbrosis the in vitro function (i.e. forskolin-
induced swelling) of the CFTR mutant protein was recovered by CFTR
function-restoring drugs or by lowering temperature [131]. Taken to-
gether, the intestinal organoids can be utilized not only to investigate
the crucial aspects of gastrointestinal biology, but their usage could
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4. Tumor formation in the intestine
Deregulation of Wnt signaling is associated with onset of cancer,
most notably carcinoma of the colon and rectum (reviewed in [132]).
It is presumed that in colorectal tumors the ﬁrst oncogenic mutation
provides selective advantage to the epithelial cell that multiplies and
generates a tiny clump of cells called microadenoma. In the majority
of sporadic colorectal tumors these “initiatory” mutations frequently
occur in the APC gene. Subsequent mutations in other genes, such as
TP53 (encodes p53 protein), phosphatase and tensin homolog (PTEN),
mothers against decapentaplegic homolog 4 (SMAD4), Kirsten rat sarcoma
viral oncogene homolog (KRAS), and phosphatidylinositol-4,5-
bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) are followed by
clonal expansion of transformed cells [133,134]. The process generates
a malignant tumor that can invade through the basement membrane
and eventually spread to distant organs [135].
Germinal mutations of the APC gene underlie a hereditary neoplastic
syndrome, the Familial Adenomatous Polyposis (FAP) [136,137]. The
FAP-affected individuals carry one defective copy of the APC gene and
develop hundreds of benign colonic APC-deﬁcient lesions termed
polyps. The polyps progress towardsmalignancy through ordered histo-
pathological stages that include high-grade dysplasia, adenoma and in-
vasive adenocarcinoma [138]. As in the case of sporadic cancer this
stepwise evolvement is driven by successive accumulation of additional
mutations [139]. HyperactiveWnt signalingmight also result frommu-
tational inactivation of theAXIN1 [140] or AXIN2 [141] genes. Finally, ap-
proximately 5% of colorectal carcinomas (CRCs) contain mutations that
compromise the N-terminal regulatory amino acids of β-CATENIN
[142]. In either case, stabilized β-CATENINmediates inappropriate tran-
scriptional activation of the TCF-β-CATENIN target genes, thus driving
pathological transformation of the gut epithelium [143,144]. Themajor-
ity of changes in the APC gene are frame-shift or nonsense mutations
(reviewed in [145]) that result in production of truncated polypeptides
retaining some residual capacity to reduce β-catenin-dependent tran-
scription. The capacity differs according to the extent of the APC trunca-
tion with longer proteins being more effective than the shorter APC
variants [146–148]. Interestingly, in FAP-affected individuals various
clinical manifestations of the disease correlate with the extent of the
APC truncation (reviewed in [149]). In agreement with these observa-
tions two recent studies indicated that individual anatomical segments
of the GI tract are differentially sensitive to aberrant Wnt signaling. Le-
sions displaying excessiveWnt signaling aremainly located in the distal
colon, whereas moderate perturbations of the Wnt pathway favor
tumor development in the upper GI and right colon [150,151].
Both hereditary and sporadic forms of bowel cancer have been reca-
pitulated in experimental mouse models (reviewed in [152]). Multiple
intestinal neoplasia (Min)mice harbor a nonsense mutation in the cod-
ing region of the Apc gene [153,154]. Similarly to the FAP individuals
these mice develop numerous polyps; however, the tumor burden is
mainly located in the small intestine. Notably, the incidence and distri-
bution of gut tumors greatly vary in individual Apc-deﬁcient mouse
strains [155] (reviewed in [156]). As in the FAP patients the severity of
polyposis correlates with an “optimal” level of aberrant Wnt signaling.
Mice expressing mutated Apc protein that partially retains its ability
to inhibitWnt signaling show earlier-onset and larger andmore numer-
ous and dysplastic lesions [157]. These data support the previous notion
that a speciﬁc dosage of Wnt/β-catenin signaling, rather than constitu-
tive activation of the pathway, is essential for tumor formation
[150,158].
Inactivation of Apc throughout the mouse intestinal epithelium
using conditional (cKO) alleles of the gene instantly promotes cellular
proliferation while impairing differentiation. Affected cells thereby ac-
quire an aberrant “crypt-like” phenotype resulting in massiveexpansion of the stem cell compartment [159–161]. The growth of
Apc-deﬁcient tumors depends on the activity of theWnt pathway target
gene c-myc since deletion of the c-myc gene rescues the deleterious
changes observed upon Apc loss [162,163]. The cancer-initiating event,
i.e. the (hyper)activation of the Wnt pathway, has to occur within the
stem cell pool to be successfully propagated [164]. This was demon-
strated by targeted Apc deletion in Lgr5+ CBC cells [161] or by ectopic
expression of stabilized β-catenin in Bmi1+ [67] or CD133+ [78] cells.
In contrast, the loss of Apc in short-lived progenitors gives rise to
microadenoma that fails to transform to malignancy [161]. This “bot-
tom-up” concept was challenged by recent ﬁndings indicating that
Lgr5-negative enterocytes on the villus can de-differentiate and re-
express stem cell markers including Ascl2, Lgr5, Rnf43, and Troy. The
de-differentiation can be achieved by simultaneous perturbation of
theWnt andNF-κB pathways. The synergy betweenNF-κB andWnt sig-
naling is attributed to the interaction of the NF-κB component v-rel
reticuloendotheliosis viral oncogene homolog A (RelA)/p65 with β-
catenin. RelA-mediated recruitment of the activatory CREB-bindingpro-
tein (CBP) to TCF-β-catenin complexes enhances theWnt signaling out-
put [165]. These results supported the “top down” concept of adenoma
formation. Although the view that tumor-initiating cells originate in the
stem cell compartment is still prevailing, the two models of intestinal
carcinogenesis are possibly not mutually exclusive. Interestingly,
Myant and colleagues published a report on the critical role of NF-κB
signaling and reactive oxygen species (ROS) in tumorigenesis upon
Apc loss. Apc-deﬁcient cells display activated Rac1 that drives produc-
tion of ROS and stimulates NF-κB signaling. This leads to the stem and
progenitor cell compartment hyperproliferation and promotes cellular
transformation [166]. Theseﬁndings provided themechanistic explana-
tion why inﬂammatory signaling might increase the risk of colorectal
cancer.
Established intestinal tumors are composed of heterogeneous cell
populations, but they preserve a cellular hierarchy that is reminiscent
of the normal crypt architecture. Consistently, a minor subset of cells
display features shared with somatic stem cells such as self-renewal
and multipotency. These cells termed cancer stem cells (CSCs) sustain
progressive growth of the lesion and retain the ability to initiate
tumor when engrafted to the recipient animal [167–170]. Elevated
Wnt signaling is a hallmark of intestinal CSCs, and thereby they are
highly enriched in mRNA encoding CBC-speciﬁc genes including Ascl2,
EphB2 and Lgr5 [66,128,169,171]. Recently, the doublecortin-like kinase
1 (Dclk1) has been identiﬁed to exquisitely earmark the transformed
stem cell population. Accordingly, speciﬁc ablation of Dclk1+ cells
prevented growth of polyps spontaneously developed in Apc+/Min
mice [172].
The tumor cell interactswith itsmicroenvironment and the environ-
mental cues inﬂuence and promote various steps of tumor develop-
ment. Tumor-associated stroma includes a wide variety of cell types
including bone-marrow derived immune cells, cancer-associated ﬁbro-
blasts and myoﬁbroblasts, mesenchymal stem and endothelial cells
[173,174] (reviewed in [175]). Moreover, in mouse adenomas located
in the proximal part of the gut the CSC niche is generated bymetaplastic
Paneth cells [52]. A similar arrangement was found in colon adenomas
in which prospective CSCs are possibly supported by Paneth cell-like
deep crypt secretory cells [171]. In humans CRC tumor-resident
myoﬁbroblasts produce hepatocyte growth factor (HGF), which locally
enhances Wnt signaling activity in neighboring cells [169]. This obser-
vation plausibly explains thewell-known “β-catenin paradox” postulat-
ing that only a fraction of cells within the APC-deﬁcient tumor harbor
nuclear β-catenin protein [176,177]. Similarly, in a large proportion of
adenocarcinomas EphB2high CSCs reside closer to the stroma, whereas
transformed cells with low levels of EphB2 are positioned in the luminal
part of the tumor [66]. Of note, several studies documented that β-
catenin nuclear translocation requires—besides APC deﬁciency—input
from diverse kinases including AKT [178], RAF1 and JNK2 [179,180],
protein kinase A (PKA) [181] and P21-activated kinase 1 (PAK1) [182].
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phenotype by effect of factors secreted from stromal myoﬁbroblasts
[169]. In summary, the CSC studies support the idea that cancer cells dis-
play much more plasticity than previously anticipated. The stemness
can be elicited not only by particular changes in the genome of trans-
formed cells (as documented in the mouse model of concurrent Wnt
and NF-κB pathway activation), but also by extrinsic factors originating
from the tumor microenvironment.
The outcome of Wnt signaling is ﬁne-tuned by intriguing interplay
between the Wnt and Hippo pathways (reviewed in [183]). Hippo sig-
naling is an evolutionarily conservedmechanism involved in the control
of organ size during development and regeneration (reviewed in
[184,185]. The growth-limiting and differentiation-promoting signal is
mediated by serine/threonine kinases STE20-like protein kinase 1
(MST1; alternative nameSTK4) and relatedMST2 (STK3), which are ho-
mologous to Drosophila Hippo. The kinases form an essential part of a
protein complex that phosphorylates and inhibits Yes-associated pro-
tein (YAP) and transcriptional co-activator with PDZ-binding motif
(TAZ). YAP/TAZ associate with different transcription factors including
the TEA domain/Transcription Enhancer Factor (TEAD) family and acti-
vate genes regulating tissue growth and cellular viability. Wnt signaling
augments the levels of TAZ, which is otherwise degraded by the β-
catenin destruction complex. In detail, β-catenin interacts with TAZ
and promotes its β-TrCP-mediated ubiquitination and degradation.
Consequently, a signiﬁcant fraction of genes regulated by theWnt path-
way depend on TAZ/TEAD. Furthermore, TAZ activates a considerable
portion of genes in APC-deﬁcient CRC cells [186]. The other Hippo exec-
utor YAP1 interacts with β-catenin and together with the transcription
factor T-box protein 5 (TBX5) they form a tripartite complex. The com-
plex drives transcription of antiapoptotic genes such as BCL2-like 1
(BCL2L1) and baculoviral IAP repeat containing 5 (BIRC5) in cancer cells.
YES1, Src-like kinase, is essential for the formation of the YAP1-β-caten-
in-TBX5 complex on the target promoters. Hence, YES1 inhibition by
cancer drug dasatinib suppresses growth of tumors dependent on the
β-catenin transcription activity [187]. Recently, Jeong and colleagues
discovered a novel mechanism controlling cellular abundance of the
Ras protein, which similarly to TAZ degradation involves the β-catenin
destruction complex. Ras is subjected to direct phosphorylation by
GSK3β that primes it forβ-TrCP recognition and subsequent destruction
in the proteasome. Moreover, a positive correlation between Ras stabi-
lization, aberrant Wnt signaling and tumorigenesis was detected in
mouse models of intestinal cancer and in human colorectal adenomas
and carcinomas [188]. In conclusion, mutational events compromising
the function of the β-catenin destruction complex might underline the
oncogenic activity of multiple signaling pathways leading to cellular
transformation and tumor formation.
5. High-throughput studies of human colorectal cancer genome
Human cancer is a genetic disease caused by mutations in tumor
suppressor genes and oncogenes. Solid tumors evolve over time from
benign to malignant lesions by acquiring genetic alterations that drive
tumor progression (reviewed in [133]). The tumor-speciﬁc mutations
give clues as to which pathways and cellular processes underlie tumor-
igenesis. In addition, a detailed knowledge about the genetic back-
ground of particular lesions has possible diagnostic and therapeutic
purposes. In the past, genes selected for mutational analysis were
known (proto)oncogenes or tumor suppressors, genes located in chro-
mosomal loci identiﬁed in linkage studies of hereditary cancer, and/or
genes functionally involved in potentially oncogenic pathways.
Recent improvements in sequencing, DNA microarray technologies
and bioinformatics enabled examination of cancer cell genomes and ex-
pression proﬁles in a detailed and comprehensive manner [189,190]. In
2006, Sjöblom and colleagues reported sequencing of a complete collec-
tion of protein-coding genes, i.e. “the exome”, derived from 11 colorec-
tal and 11 breast cancers [191]. Recently, three research consortiaanalyzed numerous human colon and rectal samples using several
state-of-the-art molecular biology approaches. Massive parallel “next-
generation” sequencing was applied to analyze the exome, tran-
scriptome and to detect gene copy-number alterations in 11 [192],
276 [134] and 72 [193] tumors and normal pairs. Moreover, single-
nucleotide polymorphisms (SNP),microsatellite instability and promot-
er methylation status were evaluated in the majority of the specimens.
This integrative molecular characterization yielded an unprecedented
insight into the pathobiology of colorectal cancer. Cancer specimens
with microsatellite instability (MSI) contained up to several thousands
of non-synonymous mutations affecting protein-coding genes on
average; the mutation rate of microsatellite-stable (MSS) CRCs was
substantially lower—these tumors contained approximately dozens of
non-synonymous alterations. The majority of these changes were
“passenger”mutationswith no effect on tumor initiation or progression.
However, each CRC—irrespective of the microsatellite stability status—
contained three to six “driver” mutations that conferred a selective
growth advantage to the cell and promoted tumorigenesis (reviewed
in [194]). Changes altering the genes involved in the Wnt signaling
pathwaywere found inmore than 90% of all tumors, including inactiva-
tion in APC or activating mutations in β-CATENIN (CTNNB1) in 80% of
cases. In contrast to MSS neoplasia, MSI tumors display lower mutation
rate of APC whilst showing enhanced numbers of alterations targeting
other Wnt cascade negative regulators. Mutations and/or deletions
were found in AXIN2, SOX9, as well as in the DKK family members and
F-box and WD repeat domain containing 7 (FBXW7) gene (FBXW7 en-
codes a subunit of the β-catenin destruction complex). TCF4 (TCF7L2)
was mutated in 31% of MSI and in 12% of MSS cancers. Moreover, the
TCF4 locus was deleted in a subset of the examined cases [134]. In ap-
proximately 3% of CRCs an intrachromosomal deletion between TCF4
and adjacent vesicle transport through interaction with t-SNAREs 1A
(VTI1A) was observed [134,192]. In three separate cases the 3′ coding
part of TCF3 (TCF7L1) on chromosome 2 was fused to the chromosome
11 region containing the neuron navigator 2 (NAV2) gene on chromo-
some 11 [134]. Both types of rearrangements are “in-frame”, thus pro-
ducing fusion polypeptides that lack the β-catenin binding domain of
the TCF partner. Bass and colleagues reported that the VTI1A-TCF4 pro-
tein promotes anchorage-independent growth of cancer cells [192];
however, how the fusion molecules contribute to tumorigenesis re-
mains elusive. In addition, Seghagiri and colleagues identiﬁed additional
rearrangements involving the RSPO family members in 10% of colon tu-
mors. The detected alterations generate fusion of either RSPO2 or the
eukaryotic translation initiation factor 3, subunit E (EIF3E) gene or
RSPO3 and the protein tyrosine phosphatase, receptor type, K (PTPRK)
gene [193]. The RSPO2-EIF3E fusion produces functional (i.e. translated)
transcript of RSPO2 driven by the EIF3E promoter. The RSPO3–PTPRK re-
arrangements represent in-frame fusions that preserve RSPO3-coding
exons except for the signal peptide sequence, which is replaced by the
secretion signal of PTPRK. In minor cases RSPO3 inversions were
found placing the gene in the proximity of PTPRK. Interestingly, the ex-
pression of RSPO2 and RSPO3 in tumors containing the rearrangements
was elevated compared to sampleswithout the fusions. Since all RSPO2/
3 fusion proteins retained biological activity and occurred in a mutually
exclusive manner with the APCmutations, they likely represent onco-
genic drivers that circumvent intact APC [193].
Intriguingly, many tumors that harbor APCmutations contain addi-
tional alterations in gene(s) encoding the Wnt pathway components;
moreover, a fraction of MSS and MSI tumors exhibit marked over-
expression of the Wnt receptor Frizzled 10 (FZD10). This implies that
multiple changes affecting Wnt signaling confer selective advantage to
the transformed cell. In concordancewith these ﬁndings, several agents
that combat tumors by interfering with aberrant Wnt signaling were
developed in recent years. Growth of Wnt-driven cancers can be sup-
pressed by Frizzled- [195] or LRP6-speciﬁc (“blocking”) [196] antibodies
or by treatment with soluble Frizzled acting as a Wnt “decoy” receptor
[197]. Importantly, smallmolecule inhibitor LGK-974, which speciﬁcally
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gates posttranslational processing of Wnt ligands [198], entered the
phase I clinical trial http://clinicaltrials.gov/show/NCT01351103 [199].
Therapeutic intervention in tumors containing defects in theWnt path-
way components downstream of the receptor complex might include
inhibitors of tankyrase, enzyme that regulates stability of the β-
catenin destruction complex through AXIN2 by poly(ADP-ribosyl)
ation [198,200]. Tankyrase inhibitors stabilize Axin and promote β-
catenin degradation even in tumor cells containing mutated APC
[201,202]; such inhibitors thus represent particularly promising phar-
maceutical reagents. Finally, the interaction of β-catenin with its tran-
scriptional partners TCF4 [203,204] or BCL9 [205] can be disrupted via
tailored peptides. In summary, high-throughput analyses of tumor spec-
imens have supported the previous assumption that effective drugging
of the aberrant Wnt pathway might be essential for cancer treatment
(reviewed in [206,207].
6. Concluding remarks
In this review, we summarized our understanding of the unique
properties and activity of intestinal stem cells. The state-of-the-art evi-
dence is changing the concept of co-existence of two distinct stem-cell
populations within the crypt. Instead, the crypt cells display consider-
able plasticity that can reverse the cell hierarchy. In either case, the ho-
meostatic self-renewal of the gut epithelium is driven by the signaling
activity of secreted Wnt proteins. Moreover, the Wnt cues are required
to reestablish the normal crypt architecture following mucosal injury.
Perturbations within the Wnt pathway initiate tumor development
and malignant progression of intestinal neoplasia. In recent years, inte-
grative studies including systematic sequencing of large numbers of co-
lorectal tumors generated an unprecedented insight into the molecular
basis of colorectal cancer. These studies underpinned the role of theWnt
pathway in cancerogenesis. Finally, these studies provided the rationale
for design and production of anti-tumor agents combating cancer by in-
terfering with aberrant Wnt signaling.
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